Paul Rubin News
Most Popular Paul Rubin Story
Emerging Drug Developer: Resolvyx Pharmaceuticals
Resolvyx builds on a 100-million-year toxicity study Resolvyx Pharmaceuticals is taking a cue from nature and turning it into new therapeutics. In their case, the cue comes from the tonic qualities... Read more...
Latest Headlines
- April 22, 2008
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
